Lab monitoring was often collected in pemphigus clinical trials, with anti‐desmoglein 1 and 3 levels being assessed in 28.3% of clinical trials, and immunoglobulins (IgG and/or IgM and IgA) (11.32%) and drug pharmacokinetics (9.4%) being frequently assessed as well (Table 4). This evidence concerns the gene DSG1 and pemphigus.